Peptide · Fact sheet
Lixisenatide
Also known as Adlyxin · Lyxumia · lixisenatide acetate · Soliqua 100/33 (with insulin glargine)
Lixisenatide has an FDA-approved adult diabetes use within Soliqua 100/33, the insulin glargine/lixisenatide combination. Standalone Adlyxin is discontinued. Lixisenatide is not approved for Parkinson disease or neuroprotection, and its Phase 2 Parkinson signal needs larger confirmation.
What is Lixisenatide?
Lixisenatide is a peptide GLP-1 receptor agonist developed for glucose control in type 2 diabetes.
Soliqua 100/33 contains both insulin glargine and lixisenatide; its approval and risks belong to that combination. Adlyxin was the standalone U.S. product.
Interest in Parkinson disease comes from possible brain and inflammatory effects of GLP-1 signaling, not from a diabetes approval.
Benefits & claims
The LIXIPARK trial reported less worsening on a motor score than placebo after one year.
That signal contrasts with a negative Phase 3 exenatide trial and makes replication, molecule differences, and study design especially important.
What the evidence supports
- LIXIPARK found less average worsening on the primary motor score than placebo over the controlled period.
- The study was not large enough to establish routine treatment, long-term disease modification, or broad class efficacy.
Research areas
- Type 2 diabetes
- Early Parkinson disease
- Motor disability progression
- GLP-1 neurobiology
- Parkinson disease progression and neuroprotection
Dosage & frequency
Product-specific label informationSoliqua 100/33 is a labeled adult diabetes combination of insulin glargine and lixisenatide. Standalone Adlyxin is discontinued; its historical microgram regimen is separate.
Soliqua 100/33 combination
Adults with type 2 diabetes
- Amount
- 15–60 insulin units of the fixed combination; maximum 60 units includes 20 mcg lixisenatide
- Frequency
- Once daily, within one hour before the first meal
- Route studied or labeled
- Subcutaneous
Starting amount depends on prior treatment; glucose-guided insulin titration and full-label safeguards apply. Not a standalone lixisenatide amount.
Adlyxin: historical label
Adults with type 2 diabetes
- Amount
- 10 mcg for 14 days, then 20 mcg
- Frequency
- Once daily
- Route studied or labeled
- Subcutaneous
Historical U.S. label; standalone product is discontinued.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Soliqua 100/33 remains a separate labeled insulin glargine/lixisenatide combination for adult type 2 diabetes; its insulin-unit-based regimen cannot be taken from the historical Adlyxin amount.
Interactions & precautions
- Insulin or insulin secretagogues increase hypoglycemia risk; delayed gastric emptying can affect oral medicines.
What is still unresolved
- A historical label does not establish current availability or approval for neurologic disease.
Side effects & risks
- Nausea and vomiting were frequent in the Parkinson trial and affected tolerability.
- The Soliqua 100/33 label warns about pancreatitis, severe gastrointestinal reactions, kidney injury, hypoglycemia, and serious hypersensitivity. Its insulin component creates additional risks that cannot be assigned to lixisenatide alone.
- The approved insulin combination, historical standalone product, and investigational Parkinson treatment are distinct formulations and evidence contexts.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Moderate human evidenceDiabetes evidence supports product-specific labeling, including the insulin glargine combination. The moderate rating reflects the Parkinson research emphasized here: a relatively small Phase 2 trial with a motor-score signal, substantial gastrointestinal adverse effects, and no proof of disease modification.
Studies
Controlled early-Parkinson study reporting a motor-score signal and gastrointestinal adverse effects.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Appetite: reported experiences
Glucose remained high early in treatment
A Lyxumia forum participant described persistently high glucose and continued appetite after two weeks, while also taking metformin and following a lower-carbohydrate diet.
Reported use in this account
- Product
- Lyxumia
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two weeks
Other exposures described: Metformin; A lower-carbohydrate diet
This July 2014 comment is an early, unverified observation during ongoing treatment changes. It does not establish longer-term effectiveness.
Read the original accountDigestion: reported experiences
Strong nausea on starting Lyxumia
A person describing type 1 diabetes reported severe nausea on the first day of an off-label Lyxumia trial for unspecified other issues.
Reported use in this account
- Product
- Lyxumia; the source's amount has an unresolved unit
- Amount
- Not specified clearly
- Frequency
- Every other day, as reported
- Route
- Not specified clearly
- Duration
- First day of use
The source's amount has an unresolved unit and is not reproduced. There is no clinical follow-up; this does not establish an approved use in type 1 diabetes.
Read the original accountGlucose: reported experiences
Glucose remained high early in treatment
A Lyxumia forum participant described persistently high glucose and continued appetite after two weeks, while also taking metformin and following a lower-carbohydrate diet.
Reported use in this account
- Product
- Lyxumia
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two weeks
Other exposures described: Metformin; A lower-carbohydrate diet
This July 2014 comment is an early, unverified observation during ongoing treatment changes. It does not establish longer-term effectiveness.
Read the original accountBetter reported glucose control with a combination
A commenter described improved HbA1c over less than three months on an insulin-glargine/lixisenatide combination, without noticeable side effects.
Reported use in this account
- Product
- Insulin-glargine/lixisenatide combination
- Amount
- 15 units of the combination initially, later 34 units; no separate lixisenatide amount stated
- Frequency
- Each morning
- Route
- Not specified clearly
- Duration
- Less than three months for the reported HbA1c change
Other exposures described: Insulin glargine within the same product; New continuous glucose monitoring
Insulin and glucose-monitoring changes were also involved. The improvement cannot be attributed to lixisenatide alone, and laboratory values were not verified.
Read the original accountNo clear change: reported experiences
Glucose remained high early in treatment
A Lyxumia forum participant described persistently high glucose and continued appetite after two weeks, while also taking metformin and following a lower-carbohydrate diet.
Reported use in this account
- Product
- Lyxumia
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Not specified clearly
- Duration
- Two weeks
Other exposures described: Metformin; A lower-carbohydrate diet
This July 2014 comment is an early, unverified observation during ongoing treatment changes. It does not establish longer-term effectiveness.
Read the original accountApproval status
FDA lists Soliqua 100/33 as a prescription product approved with diet and exercise for glycemic control in adults with type 2 diabetes. The standalone Adlyxin presentations are discontinued; this does not establish withdrawal of their approval. Neither product is approved for Parkinson disease.
Approved uses
- Glycemic control in adults with type 2 diabetes through Soliqua 100/33 (insulin glargine/lixisenatide), alongside diet and exercise
Diabetes combination approved; standalone product discontinued
Soliqua 100/33 combines insulin glargine and lixisenatide for glycemic control in adults with type 2 diabetes. FDA lists this combination as prescription and standalone Adlyxin as discontinued. Neither diabetes approval establishes an approved Parkinson use.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Whether a larger confirmatory Parkinson trial will reproduce the motor signal
- Whether the effect is symptomatic or disease modifying
- Longer-term neurologic outcomes and tolerability
- Why lixisenatide and exenatide trials produced different results
Summary
Lixisenatide offers a Parkinson research signal that needs confirmation. Soliqua 100/33 has an adult diabetes approval; discontinued standalone Adlyxin and experimental neurologic treatment remain separate contexts.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA Purple Book: Soliqua 100/33 product status
FDA record identifying the insulin glargine/lixisenatide combination and its prescription marketing status.
- fdaFDA prescribing information: Soliqua 100/33
Primary source for the practical reference information.
- fdaFDA Purple Book: Adlyxin product status
FDA record showing approval details and discontinued marketing status.
- fdaFDA prescribing information: Adlyxin
Former diabetes indication, warnings, adverse reactions, and clinical evidence.
- pubmedLIXIPARK randomized Phase 2 trial
Controlled early-Parkinson study reporting a motor-score signal and gastrointestinal adverse effects.
- nihSoliqua 100/33 current prescribing information
Current insulin glargine/lixisenatide combination labeling; not interchangeable with historical standalone Adlyxin.